Press release
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
Commercial manufacture of Kostaive® on track for delivery of initial 4 million doses in Q3 Kostaive® European Marketing Authorization Application approval
About this update from Arcturus Therapeutics Holdings Inc.
[{"type":"text","content":"\nCommercial manufacture of Kostaive® on track for delivery of initial 4 million doses in Q3\n\n\nKostaive® European Marketing Authorization Application approval decision expected Q3\n\n\nMultiple Kostaive® Phase 3 trials further demonstrate breadth and durability of STARR® vaccine platform\n\n\nARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data, anticipated in Q3\n\n\nARCT-810 (LUNAR-OTC) Phase 2 and ARCT-032 (LUNAR-CF) Phase 1b interim data and update to be provided on July 1st\n\n\nJP Morgan engaged to monetize investment in ARCALIS JV in Japan\n\n\nInvestor conference call at 4:30 p.m. ET today\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nArcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided corporate updates.\n\n\n“Arcturus continues to make encouraging progress in both our vaccine and therapeutics pipeline,” said Joseph Payne, President & CEO of Arcturus. “In collaboration with our global vaccine partner CSL and their partner Meiji Seika Pharma, we are excited to begin the commercialization of Kostaive this year.”\n\n\nMr. Payne continued, “We also look forward to providing meaningful clinical study data updates July 1st, for each of our flagship mRNA therapeutic programs, ARCT-810 (OTC deficiency) and ARCT-032 (CF).”\n\n\n“I am pleased to announce that we have engaged JP Morgan to monetize our stake in ARCALIS, our JV manufacturing operation in Japan,” stated Andrew Sassine, Chief Financial Officer of Arcturus Therapeutics. “Additionally, I am pleased to announce we will begin to qualify for commercial milestones under our CSL collaboration upon commencement of Kostaive revenues in Japan this year. Finally, our cash runway remains strong for at least three years into the first quarter of fiscal year 2027.”\n\n\nRecent Corporate Highlights\n\n\n\nIn March, Meiji Seika Pharma announced plans to supply Japan with 4 million doses of Kostaive for fall/winter season of 2024. To support this effort, Arcturus along with CDMO partners are on track to deliver the initial 4 million commercial doses of Kostaive in Q3.\n\n\n\nIn March, the Company, a...